Comment: I would like to suggest the coverage for Macugen be extended to the treatment of diabetic macular edema. Macugen is a selective anti-VEGF drug which has been approved for the use in exudative ARMD. The injection of Macugen in the treatment of diabetic macular edema has been shown to be effective in improving the vision of patients with diabetic macular edema in the recently published a...

Diabetic macular edema (DME) is arguably one of the most important challenges in ophthalmology. Macular edema refractory to laser photocoagulation remains the most prevalent cause of untreatable vision loss in diabetes and is responsible for visual disability in millions of people worldwide. The lack of an effective therapeutic solution accounts for the range of interventions proposed. These in...

UNLABELLED Diabetic macular edema (DME), one the most prevalent causes of visual loss in industrialized countries, may be diagnosed at any stage of diabetic retinopathy. The diagnosis, treatment, and follow up of DME have become straightforward with recent developments in fundus imaging, such as optical coherence tomography. Laser photocoagulation, intravitreal injections, and pars plana vitrec...

Diabetic macular edema (DME) remains the most common cause of vision loss among diabetic patients. New understanding of the underlying pathophysiology has interest in the potential benefits of the specific pharmacologic therapy, such as treatment with intraocular steroids, anti-vascular endothelial growth factor (VEGF), and protein kinase C-beta (PKCβ) inhibition. At the last time, laser photoc...

The purpose of this study was to investigate the diagnostic properties of a 2-laser wavelength nonmydriatic 200° ultra-wide-field scanning laser ophthalmoscope (SLO) versus mydriatic 2-field 45° color fundus photography (EURODIAB standard) for assessing diabetic retinopathy (DR). A total of 143 consecutive eyes of patients with different levels of DR were graded regarding DR level and macular e...

Background: 26 million people were estimated to be affected by diabetes in 2010 across the globe. Diabetic macular edema (DME) is the most important cause of visual impairment due to diabetic retinopathy. Optical Coherence Tomography (OCT) is a non-invasive modality which produces cross-sectional or three-dimensional, high-resolution images of the retinal layers and quantitative assessment of r...

The Early Treatment Diabetic Retinopathy Study (ETDRS) and other standardized classification schemes have laid a foundation for tremendous advances in the understanding and management of diabetic retinopathy (DR). However, technological advances in optics and image analysis, especially optical coherence tomography (OCT), OCT angiography (OCTa), and ultra-widefield imaging, as well as new discov...

Purpose: To evaluate the effect of intraviteral bevacizumab (IVB) in diabetic macular edema (DME), using multifocal electroretinography (mfERG) Methods: Sixty-four eyes of 32 patients with bilateral symmetric clinically significant macular edema (CSME) were included in the study. After taking a baseline mfERG, macular photocoagulation (MPC) was done in all eyes. After 7 days, 1.25 mg of bevaciz...

PURPOSE To compare intravitreal triamcinolone acetonide (IVT) versus natural course in refractory diabetic macular edema. METHODS In a prospective interventional case series, twenty five eyes with refractory DME which had been allocated to the sham group of a previous clinical trial underwent new examination and optical coherence tomography about 9 months after their first enrollment. Twenty ...